Generic Name and Formulations:
Hyaluronic acid 20mg/mL; viscoelastic gel for intra-articular inj.
Indications for DUROLANE:
Symptomatic treatment of mild-to-moderate knee or hip osteoarthritis.
Remove joint effusion before inj. Give as a single intra-articular inj. 3mL per knee or hip. Local anesthetic by SC inj or topical freezing agents may be used prior to inj. Use separate syringes for each joint.
Do not inject by intravascular or extra-articular route, or in the synovial tissues or capsule. Avoid infected or severely inflamed synovial joint, active skin disease or infection at or near inj site. Venous or lymphatic stasis in the leg. Pre-existing chondrocalcinosis. Hyaluronic acid sensitivity. Avoid strenuous activity within 48hrs after injection. Pregnancy, nursing mothers: not studied.
Concomitant other intra-articular injectables: not established.
Transient pain, swelling, joint stiffness; infection.
Single-use prefilled syringe (3mL)—1
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Ivacaftor Improves Insulin Secretion in Children With Cystic Fibrosis
- Genetic Testing Recommended for Familial Hypercholesterolemia
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry